PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media288502ArticlesСтатьиResearch ArticlePodderzhivayushchaya terapiya pri bipolyarnom affektivnom rasstroystveПоддерживающая терапия при биполярном аффективном расстройствеUshkalovaA. VУшкаловаА. В

к.м.н., врач-психиатр, отделение психиатрии и психотерапии Европейского медицинского центра

UshkalovaE. AУшкаловаЕ. А

д.м.н., проф. кафедры общей и клинической фармакологии РУДН

eushk@yandex.ruЕвропейский медицинский центрРУДН10122015223SNOs3 (2015)№s3 (2015)61226022023Copyright ©; 2015, Bionika MediaCopyright ©; 2015, ООО «Бионика Медиа»2015Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/288502

Selection of the optimal maintenance pharmacotherapy in bipolar affective disorder (BAR) is complicated by the limited availability of comparative evidence that makes the difference in the recommended first- and second-line drugs in various treatment guidelines. The article presents the evidence base for the main groups of drugs used for the treatment of BAR. It is noted that monotherapy with one of first-line drugs, which proved to be effective as a preventive measure, is justified for maintenance treatment in most patients with BAR.

Выбор оптимальной поддерживающей фармакотерапии при биполярном аффективном расстройстве (БАР) затрудняет ограниченность имеющихся сравнительных доказательных данных, что обусловливает разницу в рекомендуемых препаратах первой и второй линий в различных руководствах по лечению. В статье приведена доказательная база по основным группам препаратов, использующихся для терапии БАР. Отмечено, что большинству пациентов с БАР для поддерживающего лечения показана монотерапия одним из препаратов первой линии, доказавшим свою эффективность в качестве профилактического средства.

bipolar affective disordermaintenance therapypreventionбиополярное аффективное расстройствоподдерживающая терапияпрофилактикаGoodwin F.K., Jamison K. Manic-depressive illness. In: Bipolar disorders and recurrent depression. 2nd ed. Cambridge: Oxford Press, 2007.Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder. Lancet. 2013; 381(9878): 1672-82.Pfennig A., Bschor T., Falkai P., Bauer M. The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline. Dtsch. Arztebl. Int. 2013; 110(6): 92-100.Vieta E., Valenti M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013; 27(7): 515-29.Grunze H., Vieta E., Goodwin G., Bowden C., Licht R.W., Moller H.J., Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2009 on the treatment of bipolar depression. World J. Biol.6. Yatham L.N., Kennedy S.H., Parikh S.V., Schaffer A., Beaulieu S., Alda M., O'Donovan C., Macqueen G., McIntyre R.S., Sharma V., Ravindran A., Young L.T., Milev R., Bond D.J., Frey B.N., Goldstein B.I., Lafer B., Birmaher B., Ha K., Nolen W.A., Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar DisordGoodwin G.M. and Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J. Psychopharmacol.2009; 23: 346-88.Kasper S., Calabrese J.R., Johnson G., Tajima O., Vieta E. International Consensus Group on the Evidence-based Pharmacological Treatment of Bipolar I and II Depression. J. Clin. Psychiatr. 2008; 69 (10): 1632-46.NICE Clinical Guidelines. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence, 2009.National Institute for Health and Care Excellence (NICE). The assessment and management of bipolar disorder in adults, children and young people in primary and secondary care, updated edition. London: NICE; 2014. www.nice.org.uk/CG185.Burgess S., Geddes J., Hawton K., Townsend E., Jamison K., Goodwin G. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev. 2001; (3): CD003013.Davis J.M., Janicak P.G., Hogan D.M. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr. Scand. 1999; 100(6): 406-17.Geddes J.R., Burgess S., Hawton K., Jamison K., Goodwin G.M. Long-term lithium therapy for bipolar disorder: systematic review and metaanalysis of randomized controlled trials. Am. J. Psychiatry. 2004; 161(2): 217-22.Fountoulakis K.N., Kasper S., Andreassen O., Blier P., Okasha A., Severus E., Versiani M., Tandon R., Muller H.J., Vieta E. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur. Arch. Psychiatr. Clin. Neurosci. 2012; 262 (Suppl 1): 1-48.Frye M.A., Yatham L.N., Calabrese J.R., Bowden C.L., Ketter T.A., Suppes T., Adams B.E., Thompson T.R. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J. Clin. Psychiatry.2006: 67: 1721-728.Post R., Leverich G., Altshuler L., Mikalauskas K. Lithium discontinuation-induced refractoriness: preliminary observations. Am. J. Psychiatr. 1992; 149: 1727.Frye M.A., Yatham L., Ketter T.A., Goldberg J., Suppes T., Calabrese J.R., Bowden C.L., Bourne E., Bahn R.S., Adams B. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatr. Scand. 2009; 120: 10-13.Nolen W.A., Weisler R.H. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who respond to quetiapine (Trial 144). Bipolar. Disord. 2013; 15(1): 100-09.Calabrese J.R., Bowden C.L., Sachs G., Yatham L.N., Behnke K., Mehtonen O.P., Montgomery P., Ascher J., Paska W., Earl N., DeVeaugh-Geiss J.; Lamictal 605 Study Group. A placebo controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatr. 2003; 64(9): 1013-24.Bowden C.L., Calabrese J.R., Sachs G., Yatham L.N., Asghar S.A, Hompland M., Montgomery P., Earl N., Smoot T.M., DeVeaugh-Geiss J.; Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatr.2003; 60(4): 392-400.Weisler R.H., Nolen W.A., Neijber A., Hellqvist A., Paulsson B. Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J. Clin. Psychiatr. 2011; 72(11): 1452-64.Severus E., Taylor M.J., Sauer C., Pfennig A., Ritter P., Bauer M., Geddes J.R. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int. J. Bipolar. Disord. 2014; 2: 15.Miura T., Noma H., Furukawa T.A., Mitsuyasu H., Tanaka S., Stockton S., Salanti G., Motomura K., Shimano-Katsuki S., Leucht S., Cipriani A., Geddes J.R., Kanba S. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014; 1(5): 351-59.Abou-Saleh M.T., Coppen A. Who responds to prophylactic lithium? J. Affect Disord. 1986; 10(2): 115-25.Fountoulakis K.N., Kontis D., Gonda X., Yatham L.N. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2013; 15(2): 115-37.Geller B., Cooper T.B., Watts H.E., Cosby C.M., Fox L.W. Early findings from a pharmacokineti-cally designed double-blind and placebo-controlled study of lithium for adolescents comorbid with bipolar and substance dependency disorders. Prog. Neuropsychopharmacol. Biol. Psychiatr. 1992; 16(3): 281-99.Geller B., Cooper T.B., Sun K., Zimerman B., Frazier J., Williams M., Heath J. Double-blind and placebocontrolled study of lithium for adolescent bipolar disorders with secondary substance dependency. J. Am. Acad. Child. Adolesc. Psychiatr. 1998; 37: 171-78.Calabrese J.R., Shelton M.D., Rapport D.J., Youngstrom E.A., Jackson K., Bilali S., Ganocy S.J., Findling R.L. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am. J. Psychiatr.2005; 162: 2152-161.Baldessarini R.J., Tondo L., Davis P., Pompili M., Goodwin F.K., Hennen J. Decreased risk of suicides and attempts during long term lithium treatment: a meta-analytic review. Bipolar. Disord. 2006; 8(5 Pt 2): 625-39.30. Gonzalez-Pinto A., Mosquera F., Alonso M., Lopez P., Ramirez F., Vieta E., Baldessarini R.J. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006; 8(5 Pt 2): 618-24Cipriani A., Pretty H., Hawton K., Geddes J.R. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomised trials. Am. J. Psychiatr. 2005; 162: 1805-19.Albert U., De Cori D., Blengino G., Bogetto F., Maina G. [Lithium treatment and potential longterm side effects: a systematic review of the literature]. Riv. Psichiatr. 2014; 49(1): 12-21.Nolen W.A. More robust evidence for the efficacy of lithium in the long-term treatment of bipolar disorder: should lithium (again) be recommended as the single preferred first-line treatment? Int. J. Bipolar. Disord. 2015; 3: 1.Elnazer H.Y., Sampson A., Baldwin D. Lithium and sexual dysfunction: an under-researched area. Hum Psychopharmacol. 2015 Jan 26. [Epub ahead of print]Goldsmith D.R., Wagstaff A.J., Ibbotson T., Perry C.M. Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003; 63(19): 2029-50.Cipriani A., Reid K., Young A.H., Macritchie K., Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst. Rev. 2013; 10: CD003196.Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., Pope H.G. Jr, Chou J.C., Keck P.E. Jr., Rhodes L.J., Swann A.C., Hirschfeld R.M., Wozniak P.J. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry. 2000; 57(5): 481-89.BALANCE investigators and collaborators, Geddes J.R., Goodwin G.M., Rendell J., Azorin J.M., Cipriani A., Ostacher M.J., Morriss R., Alder N., Juszczak E. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010; 375(9712): 385-95.Beynon S., Soares-Weiser K., Woolacott N., Duffy S., Geddes J.R. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J. Psychopharmacol. 2009; 23: 574-591.Oquendo M.A., Galfalvy H.C., Currier D., Grunebaum M.F., Sher L., Sullivan G.M., Burke A.K., Harkavy-Friedman J., Sublette M.E., Parsey R.V., Mann J.J. Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am. J. Psychiatry. 2011; 168: 1050-056.Nguyen H.T., Sharma V., McIntyre R.S. Teratogenesis associated with antibipolar agents. Adv. Ther. 2009; 26(3): 281-94.Minagawa K., Watanabe T., Oyanagi R. [Characteristics of women with epilepsy who developed polycystic ovary syndrome owing to the therapy with valproate sodium]. No To Hattatsu. 2013; 45(4): 304-08.Gentile S. Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions. CNS Spectr. 2014; 19(4): 305-15.Okuma T., Inanaga K., Otsuki S., Sarai K., Takahashi R., Hazama H., Mori A., Watanabe S. A preliminary double blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology. 1981; 73(1): 95-6.Vieta E., Cruz N., Garci'a-Campayo J., de Arce R., Manuel Crespo J., Valles V., Perez-Blanco J., Roca E., Manuel Olivares J., Morinigo A., Fernandez-Villamor R., Comes M. A double-blind, randomized, placebo controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int. J. Neuropsychopharmacol. 2008; 11(4): 445-52.Kukopulos A., Reginaldi D., Laddomada P., Floris G., Serra G., Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr. Neuropsychopharmakol. 1980; 13(4): 156-67.Vieta E., Goikolea J.M. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar. Disord.2005; 7(Suppl. 4): 21-33.Tohen M., Greil W., Calabrese J.R., Sachs G.S., Sachs G.S., Yatham L.N., Oerlinghausen B.M., Koukopoulos A., Cassano G.B., Grunze H., Licht R.W., Dell'Osso L., Evans A.R., Risser R., Baker R.W., Crane H., Dossenbach M.R., Bowden C.L. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-90.Tohen M., Ketter T.A., Zarate C.A., Suppes T., Frye M., Altshuler L., Zajecka J., Schuh L.M., Risser R.C., Brown E., Baker R.W. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. Psychiatry. 2003; 160: 1263-71.Ketter T.A., Houston J.P., Adams D.H., Risser R.C., Meyers A.L., Williamson D.J., Tohen M. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J. Clin. Psychiatr. 2006; 67(1): 95-101.Cipriani A., Rendell J., Geddes J.R. Olanzapine in long-term treatment of bipolar disorder: a systematic review and metaanalysis. J Psychopharmacol. 2010; 24(12): 1729-38.Keck P.E. Jr, Calabrese J.R., McIntyre R.S., McQuade R.D., Carson W.H., Eudicone J.M., Carlson B.X., Marcus R.N., Sanchez R.; Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J. Clin. Psychiatry. 2007; 68(10): 1480-91.Keck P.E. Jr, Calabrese J.R., McQuade R.D., Carson W.H., Carlson B.X., Rollin L.M., Marcus R.N., Sanchez R.; Aripiprazole Study Group. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatr. 2006; 67(4): 626-37.Fountoulakis K.N., Vieta E., Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. J. Affect Disord. 2011; 133(3): 361-70.Weisler R.H., Nolen W.A., Neijber A., Hellqvist A., Paulsson B. Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: A randomized controlled study). J. Clin. Psychiatr. 2011; 72 (11): 1452-464.Vieta E., Calabrese J.R., Goikolea J.M., Raines S., Macfadden W. BOLDER Study Group. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo controlled study. Bipolar. Disord. 2007; 9(4): 413-25.Berwaerts J., Melkote R., Nuamah I., Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J. Affect Disord. 2012; 138(3): 247-58.Quiroz J.A.,Yatham L.N., Palumbo J.M., Karcher K., Kushner S., Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol. Psychiatr. 2010; 68(2): 156-62.Bobo W.V., Shelton R.C. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. Expert Rev. Neurother. 2010; 10(11): 1637-58.McIntyre R.S., Cohen M., Zhao J., Alphs L., Macek T.A., Panagides J. Asenapine for longterm treatment of bipolar disorder: a doubleblind 40-week extension study. J. Affect Disord. 2010; 126(3): 358-65.McIntyre R.S., Cohen M., Zhao J., Alphs L., Macek T.A., Panagides J. Asenapine versus olanzapine in acute mania: a doubleblind extension study. Bipolar. Disord. 2009; 11(8): 815-26.Amsterdam J.D., Garcia-Espana F., Fawcett J., Quitkin F.M., Reimherr F.W., Rosenbaum J.F., Schweizer E., Beasley C. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J. Clin. Psychopharmacol. 1998; 18(6): 435-40.Amsterdam J.D., Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a doubleblind, placebo-substitution, continuation study. Int. Clin. Psychopharmacol. 2005; 20(5): 257-64.Amsterdam J.D., Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am. J. Psychiatr. 2010; 167(7): 792-800.Amsterdam J.D., Shults J., Brunswick D.J., Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolarnos major depression - low manic switch rate. Bipolar. Disord. 2004; 6(1): 75-81.Bond D.J., Noronha M.M., Kauer-Sant'Anna M., Lam R.W., Yatham L.N. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. Clin. Psychiatr. 2008; 69(10): 1589-601.Popovic D., Reinares M., Amann B., Salamero M., Vieta E. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology (Berl). 2011; 213(4): 657-67.Vieta E., Gunther O., Locklear J., Ekman M., Miltenburger C., Chatterton M.L., Aström M., Paulsson B. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. 2011; 14(8): 1029-49.Vieta E., Suppes T., Eggens I., Persson I., Paulsson B., Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J. Affect Disord. 2008; 109(3): 251-63.Suppes T., Vieta E., Liu S., Brecher M., Paulsson B.; Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am. J. Psychiatry.2009; 166(4): 476-88.Vieta E., Suppes T., Ekholm B., Udd M., Gustafsson U. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord.2012; 142(1-3): 36-44.Bowden C.L., Singh V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Expert Opin Pharmacother. 2012 Dec; 13(17): 2565-71. Cochrane Database Syst. Rev. 2013; 10: CD003196.van der Loos M.L., Mulder P., Hartong E.G., Blom M.B., Vergouwen A.C., van Noorden M.S., Timmermans M.A., Vieta E., Nolen W.A.; LamLit Study Group. Long-term outcome of bipolar depressed patients receiving lamotrigine as addon to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar. Disord 2011; 13(1): 111-17.Kemp D.E., Gao K., Ganocy S.J., Elhaj O., Bilali S.R., Conroy C., Findling R.L., Calabrese J.R. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence. J. Clin. Psychiatr. 2009; 70(1): 113-21.Tohen M., Chengappa K.N., Suppes T., Baker R.W., Zarate C.A., Bowden C.L., Sachs G.S., Kupfer D.J., Ghaemi S.N., Feldman P.D., Risser R.C., Evans A.R., Calabrese J.R. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. Mood stabiliser alone. Br. J. Psychiatr. 2004; 184: 337-45.Houston J.P., Ahl J., Meyers A.L., Kaiser C.J., Tohen M., Baldessarini R.J. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex J. Clin. Psychiatry. 2006; 67(8): 1246-52.Suppes T., Webb A., Paul B., Carmody T., Kraemer H., Rush A.J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment resistant illness and a history of mania. Am. J. Psychiatry. 1999; 156(8): 1164-69.Citrome L. Ziprasidone hcl capsules for the adjunctive maintenance treatment of bipolar disorder in adults Expert Rev. Neurother. 2010; 10(7): 1031-37.Bowden C.L., Vieta E., Ice K.S., Schwartz J.H., Wang P.P., Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J. Clin. Psychiatr. 2010; 71(2): 130-37.Marcus R., Khan A., Rollin L., Morris B., Timko K., Carson W., Sanchez R. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 2011; 13(2): 133-44.Vieta E., Nieto E., Autet A., Rosa A.R., Goikolea J.M., Cruz N., Bonet P. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J. Biol. Psychiatr. 2008; 9(3): 219-24.Macfadden W., Alphs L., Haskins J.T., Turner N., Turkoz I., Bossie C., Kujawa M., Mahmoud R. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar. Disord 2009; 11(8): 827-39.Brown E., Dunner D.L., McElroy S.L., Keck P.E., Adams D.H., Degenhardt E., Tohen M., Houston J.P. Olanzapine/fluoxetine combination vs. Lamotrigine in the 6-month treatment of bipolar I depression. Int. J. Neuropsychopharmacol. 2009; 12(6): 773-82.Corya S.A., Perlis R.H., Keck P.E. Jr, Lin D.Y., Case M.G., Williamson D.J., Tohen M.F. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J. Clin. Psychiatr. 2006; 67(5): 798-806.Altshuler L.L., Post R.M., Hellemann G., Leverich G.S., Nolen W.A., Frye M.A., Keck P.E. Jr, Kupka R.W., Grunze H., McElroy S.L., Sugar C.A., Suppes T. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J. Clin. Psychiatr. 2009; 70(4): 450-57.